Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Drop in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totalling 1,310,000 shares, a drop of 37.3% from the December 31st total of 2,090,000 shares. Based on an average daily volume of 6,420,000 shares, the short-interest ratio is presently 0.2 days. Currently, 2.3% of the company’s stock are short sold.

Aptose Biosciences Trading Up 6.2 %

Shares of APTO traded up $0.01 during midday trading on Friday, reaching $0.18. The stock had a trading volume of 221,664 shares, compared to its average volume of 749,333. The firm has a 50 day simple moving average of $0.21 and a 200-day simple moving average of $0.35. The firm has a market cap of $10.81 million, a PE ratio of -0.06 and a beta of 0.87. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.20.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on APTO. StockNews.com began coverage on shares of Aptose Biosciences in a research report on Friday, January 24th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research report on Friday, January 10th.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.